By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Vallongatan 1

Uppsala    SE-752 28  Sweden
Phone: 46-18-50-54-40 Fax: 46-18-51-08-73



Company News
Oasmia's Lead Cancer Product Paclical® Receives Market Approval In The Russian Federation 4/20/2015 11:24:02 AM
Oasmia Wins FDA Conditional Approval For Paccal Vet In Two Canine Cancers 2/28/2014 7:32:37 AM
The Oasmia Annual Report is Now Published 8/22/2013 9:57:22 AM
Oasmia Appoints New Vice President Communications 6/13/2013 8:52:40 AM
Oasmia’s Patented XR-17 Technology Generates Novel Cancer Combination Therapy 5/28/2013 9:05:03 AM
Oasmia Initiates Clinical Program With Paclical® in Metastatic Breast Cancer 5/6/2013 9:18:59 AM
Oasmia and Abbott Animal Health Sign Global Collaboration Agreement for $21.5 Million 1/9/2013 7:21:41 AM
Oasmia and Abbott Laboratories (ABT) Sign Global Collaboration Agreement for Canine Oncology Therapies 1/7/2013 9:44:34 AM
Oasmia Release: Positive Phase III Result From the Interim Analysis of the Study in Ovarian Cancer With Paclical(R) 8/2/2011 10:00:57 AM
Preliminary Analysis Indicates That Oasmia's Product Candidate Paccal(R) Vet Met Primary Endpoint in Phase III Study in Dogs With Mastocytoma 5/4/2010 9:09:26 AM